Sonoma Pharmaceuticals Inc. has entered into an amended and restated employment agreement with its Chief Executive Officer, Amy Trombly, effective October 3, 2025. Under the new agreement, Ms. Trombly will receive a base salary of $475,000 per year and will be eligible for a target annual bonus of 50% of her base salary, subject to the discretion of the Compensation Committee. If terminated without cause or for good reason, her severance will be paid through regular payroll and COBRA reimbursement will be provided for up to twelve months. In the event of termination without cause or for good reason in connection with a change in control, Ms. Trombly will receive severance of two times her annual base salary and target bonus, and COBRA reimbursement will be extended to twenty-four months. The notice period for termination has been extended to 90 days, and vested equity awards may be exercised for up to 24 months following termination.